All data are based on the daily closing price as of September 6, 2024
l
Lumosa Therapeutics
6535.TWO
7.78 USD
0.11
+1.43%
Overview
Last close
7.78 usd
Market cap
1.28B usd
52 week high
8.21 usd
52 week low
1.33 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
857.2744
Price/Book Value
29.6509
Enterprise Value
1.25B usd
EV/Revenue
837.8163
EV/EBITDA
N/A
Key financials
Revenue TTM
1.49M usd
Gross Profit TTM
N/A usd
EBITDA TTM
-10.46M usd
Earnings per Share
-0.05 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd
About
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.